erenumab
Term · Oncology and biomedicine · MLC-T-ONC-013407
A human immunoglobulin G2 (IgG2) monoclonal antibody targeting calcitonin gene-related peptide receptor (CGRPR), that can be used in the preventive treatment of migraine. Upon subcutaneous administration, erenumab specifically targets, binds to and blocks the activity of CGRPR. This may relief CGRPR-triggered migraine.
| Identifier | MLC-T-ONC-013407 |
|---|---|
| Field | Oncology and biomedicine |
| References | National Cancer Institute Thesaurus (CC BY 4.0) |
Record as JSON
{
"id": "MLC-T-ONC-013407",
"term": "erenumab",
"field": "Oncology and biomedicine",
"definition": "A human immunoglobulin G2 (IgG2) monoclonal antibody targeting calcitonin gene-related peptide receptor (CGRPR), that can be used in the preventive treatment of migraine. Upon subcutaneous administration, erenumab specifically targets, binds to and blocks the activity of CGRPR. This may relief CGRPR-triggered migraine.",
"references": [
"National Cancer Institute Thesaurus"
],
"url": "https://mlchart.com/terminology/oncology/erenumab/"
}
Record 6,847 of 17,721 in Oncology and biomedicine terminology (MLC-0111). Request the full dataset.